- Previous Close
0.0039 - Open
0.0039 - Bid 0.0040 x --
- Ask 0.0090 x --
- Day's Range
0.0039 - 0.0039 - 52 Week Range
0.0030 - 0.0223 - Volume
194,000 - Avg. Volume
5,701 - Market Cap (intraday)
470,169 - Beta (5Y Monthly) -0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial. The company has a strategic collaboration with reVision for the development of a therapy for stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
www.aequuspharma.ca--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AQSZF
View MorePerformance Overview: AQSZF
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AQSZF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AQSZF
View MoreValuation Measures
Market Cap
470.17k
Enterprise Value
5.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.37
Price/Book (mrq)
--
Enterprise Value/Revenue
17.37
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-153.07%
Return on Equity (ttm)
--
Revenue (ttm)
413.17k
Net Income Avi to Common (ttm)
-2.68M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
25.41k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.56M